GlassScriptPhysician profile
Gustavo J Marks
NPI 1740373315
$3,147.99
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $837 · 2020: $566 · 2021: $814 · 2022: $473 · 2023: $422 · 2024: $35.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $457.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $614.31 | 2019-2023 | Breztri, Farxiga |
| Lilly USA, LLC | $516.90 | 2019-2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $360.89 | 2019-2022 | |
| Novo Nordisk INC | $316.59 | 2019-2022 | |
| Abbvie INC. | $234.68 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $169.65 | 2021 | |
| Abbott Laboratories | $165.85 | 2022-2024 | Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $146.66 | 2023 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.97 | 2022-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $88.11 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.38 | 2021 | |
| Amarin Pharma, INC. | $69.11 | 2020-2021 | |
| Pfizer INC. | $67.57 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $46.51 | 2019 | |
| Radius Health, INC. | $37.03 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $25.00 | 2020 | |
| Astellas Pharma US INC | $22.90 | 2021 | |
| Idorsia Pharmaceuticals US INC | $21.48 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $21.10 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $20.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gustavo Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.